Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Brief description of study
Study to evaluate safety, tolerability, and pharmacokinetics of NUV-868 as monotherapy and in combination with olaparib or enzalutamide and evaluate antitumor activity in advanced solid tumors. Only phase 1 of the study will be done at NYU.
Clinical Study Identifier: s22-01098
ClinicalTrials.gov Identifier: NCT05252390
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.